nach oben

CNS Drugs

Erschienen in:

01.08.2003 | Current Opinion

Medical Marijuana Initiatives

Are They Justified? How Successful Are They Likely to Be?

verfasst von: Prof. Wayne Hall, Louisa Degenhardt

Erschienen in: CNS Drugs | Ausgabe 10/2003

Einloggen, um Zugang zu erhalten

Abstract

The principal constituent of cannabis, Δ⁹-tetrahydrocannabinol (THC), is moderately effective in treating nausea and vomiting, appetite loss, and acute and chronic pain. Oral THC (dronabinol) and the synthetic cannabinoid, nabilone, have been registered for medical use in the US and UK, but they have not been widely used because patients find it difficult to titrate doses of these drugs. Advocates for the medical use of cannabis argue that patients should be allowed to smoke cannabis to relieve these above-mentioned symptoms.

Some US state governments have legislated to allow the medical prescription of cannabis, but the US federal government has tried to prevent patients from obtaining cannabis and threatened physicians who prescribe it with criminal prosecution or loss of their licence to practise. In the UK and Australia, committees of inquiry have recommended medical prescription (UK) and exemption from criminal prosecution (New South Wales, Australia), but governments have not accepted these recommendations. The Canadian government allows an exemption from criminal prosecution to patients with specified medical conditions. It has recently legislated to provide cannabis on medical prescription to registered patients, but this scheme so far has not been implemented.

Some advocates argue that legalising cannabis is the only way to ensure that patients can use it for medical purposes. However, this would be contrary to international drug control treaties and is electorally unpopular. The best prospects for the medical use of cannabinoids lie in finding ways to deliver THC that do not involve smoking and in developing synthetic cannabinoids that produce therapeutic effects with a minimum of psychoactive effects. While awaiting these developments, patients with specified medical conditions could be given exemptions from criminal prosecution to grow cannabis for their own use, at their own risk.

Grinspoon L, Bakalar J. Marihuana, the forbidden medicine. New Haven (CT): Yale University Press, 1993

Mechoulam R. The pharmacohistory of cannabis sativa. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton (FL): CRC Press, 1986

Nahas G. Toxicology and pharmacology. In: Nahas G, editor. Marihuana in science and medicine. New York: Raven Press, 1984: 109–246

Kalant H. Medicinal use of cannabis: history and current status. Pain Res Manag 2001; 6(2): 80–91PubMed

Mechoulam R, Hanu L. The cannabinoids: an overview: therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag 2001; 6(2): 67–73PubMed

Iversen L. The science of marijuana. Oxford: Oxford University Press, 2000

Hall W, Degenhardt L, Lynskey M. The health and psychological consequences of cannabis use. Canberra (ACT): Australian Publishing Service, 2001

Goani Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 646–7CrossRef

Institute of Medicine. Marijuana and medicine: assessing the science base. Washington, DC: National Academy Press, 1999

10.

Ashton HC. Biomedical benefits of cannabinoids? Addict Biol 1999; 4(2): 111–26PubMedCrossRef

11.

Bagshaw SM, Hagen NA. Medical efficacy of cannabinoids and marijuana: a comprehensive review of the literature. J Palliat Care 2002; 18(2): 111–22PubMed

12.

House of Lords Select Committee on Science and Technology. Cannabis: the scientific and medical evidence. London: Stationary Office, 1998

13.

Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs 2000; 60(6): 1303–14PubMedCrossRef

14.

Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther 2002; 95(2): 127–35PubMedCrossRef

15.

Campbell FA, Tramer MR, Carrol D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323(7303): 13–6PubMedCrossRef

16.

Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323(7303): 16–21PubMedCrossRef

17.

Soderpalm AHV, Schuster A, de Wit H. Antiemetic effect of smoked marijuana: subjective and behavioural effects on nausea induced by syrup of ipecac. Pharmacol Biochem Behav 2001; 69(3-4): 343–50PubMedCrossRef

18.

Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10(2): 89–97PubMedCrossRef

19.

Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997; 14(1): 7–14PubMedCrossRef

20.

Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacol Ther 2002; 95(2): 165–74PubMedCrossRef

21.

Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997; 38(1): 44–8PubMedCrossRef

22.

Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983; 13(6): 669–71PubMedCrossRef

23.

Petro DJ, Ellenberger Jr C. Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 1981; 21(8-9 Suppl.): 413S–6SPubMed

24.

Ungerleider JT, Andyrsiak T, Fairbanks L, et al. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7(1): 39–50PubMedCrossRef

25.

Smith PF. Cannabinoids in the treatment of pain and spasticity n multiple sclerosis. Curr Opin Investig Drugs 2002; 3(6): 859–64PubMed

26.

Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58(9): 1404–7PubMedCrossRef

27.

Romero J, Lasstres-Becker I, de Miguel R, et al. The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological and therapeutic aspects. Pharmacol Ther 2002; 95(2): 137–52PubMedCrossRef

28.

Muller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette’s syndrome with delta-9-tetrahydrocannabinol (THC): a randomized cross-over trial. Pharmacopsychiatry 2002; 35: 57–61PubMedCrossRef

29.

Alward WL. Medical management of glaucoma. N Engl J Med 1998; 339(18): 1298–307PubMedCrossRef

30.

Crawford WJ, Merritt JC. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharmacol Biopharm 1979; 17(5): 191–6PubMed

31.

Green K. Marijuana smoking vs cannabinoids for glaucoma therapy. Arch Ophthalmol 1998; 116(11): 1433–7PubMed

32.

Jarvinen T, Pate DW, Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol Ther 2002; 95(2): 203–20PubMedCrossRef

33.

Swift W, Hall W. Tolerance, withdrawal and dependence. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology and therapeutic potential. New York: Haworth, 2002: 257–68

34.

Tashkin DP. Airway effects of marijuana, cocaine, and other inhaled illicit agents. Curr Opin Pulm Med 2001; 7(2): 43–61PubMedCrossRef

35.

GW Pharmaceuticals. Drug delivery technologies [online]. Available from URL: http://www.gwpharm.com/rese_drug_index.html [Accessed 2002 Dec 3]

36.

Goutopoulos A, Makriyannis A. From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol Ther 2002; 95(2): 103–17PubMedCrossRef

37.

DuPont RL. Examining the debate on the use of medical marijuana. Proc Assoc Am Physicians 1999; 111(2): 166–72PubMedCrossRef

38.

Report of the working party. Sydney (NSW): Working Party on the Use of Cannabis for Medical Purposes (NSW), 2000

39.

Pacula RL, Chriqui JF, Reichmann DA, et al. State medical marijuana laws: understanding the laws and their limitations. J Public Health Policy 2002; 23: 411–37CrossRef

40.

Conboy JR. Smoke screen: America’s drug policy and medical marijuana. Food Drug Law J 2000; 55(4): 601–17PubMed

41.

Gieringer D. The acceptance of medicinal marijuana in the US. J Cannabis Ther 2003; 3: 53–65CrossRef

42.

Barnes RE. Reefer madness: legal & moral issues surrounding the medical prescription of marijuana. Bioethics 2000; 14(1): 16–41PubMedCrossRef

43.

Reuter P, Burnam A. Drug warriors and policy reformers: the debate over medical marijuana. Rand Drug Policy Res Cent Newsl 1997; 6(1): 1–6

44.

US General Accounting Office. Marijuana: early experiences with four states’ laws that allow use for medical purposes: GAO-03-189. Washington, DC: US General Accounting Office, 2002 Nov

45.

Moffat AC. The legalization of cannabis for medical use. Sci Justice 2002; 42(1): 55–7PubMedCrossRef

46.

Health Canada Office of Cannabis Medical Access. Medical access to marijuana: how the regulations work [online]. Available from URL: http://www.hcsc.gc.ca/hecs-sesc/ocma/bckdr_1-0601.htm [Accessed 2002 Aug 30]

47.

Abraham C. Medicinal-marijuana harvest on hold. The Globe and Mail 2002 Apr 22; Sect. A: 1 (col. 3–6), 6 (col. 1–2)

48.

Hall WD, Degenhardt LJ, Currow D. Allowing the medical use of cannabis. Med J Aust 2001; 175(1): 39–40PubMed

49.

MacCoun R, Reuter P. Drug war heresies. New York: Cambridge University Press, 2001CrossRef

50.

Hall W, Babor T. Cannabis use and public health: assessing the burden. Addiction 2000; 95(4): 485-90PubMedCrossRef

Titel: Medical Marijuana Initiatives
Are They Justified? How Successful Are They Likely to Be?
verfasst von: Prof. Wayne Hall
Louisa Degenhardt
Publikationsdatum: 01.08.2003
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 10/2003
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200317100-00001

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2003

Prospects for the Pharmacotherapy of Amyotrophic Lateral Sclerosis

Effects of Antiepileptic Drugs on Sleep Structure

Neuroprotective Strategies in Parkinson’s Disease